Blood Volatile Organic Compounds as Potential Biomarkers for Amyotrophic Lateral Sclerosis: an Animal Study in the SOD1 G93A Mouse

Amyotrophic lateral sclerosis (ALS) is a rapid progressive motor neuron disease. Currently, there are no specific or reliable biomarkers for the diagnosis of this disease, and there are no effective medical treatments. The early diagnosis and treatment of this disease has the potential to prolong the survival of ALS patients, but typically, approximately 1 year passes between the onset of symptoms and the diagnosis of this disease. Therefore, there is an urgent need to find specific biomarkers to enable early diagnosis and therapeutic intervention in this disease. Analyzing the volatile organic compounds (VOCs) present in the blood and exhaled breath is a useful and convenient approach for investigating potential biomarkers. In this study, we examined the VOCs present in blood samples from copper zinc superoxide dismutase 1 (SOD1) glycine to alanine mutation at position 93 (G93A) mice to determine whether a specific biomarker pattern exists in these transgenic mice. Blood samples from ALS mice and their age-matched littermates were analyzed using gas chromatography-mass spectrometry. A total of 12 independent compounds associated with oxidative stress were identified at the early stage of disease. The data show that there is a specific pattern of blood VOCs in ALS mice that could potentially be used as biomarkers that could improve the diagnosis of this disease. Furthermore, these compounds could also potentially be used to monitor the response to neuroprotective agents and to help us better understand the underlying mechanisms of ALS.

[1]  S. W. Lin,et al.  Protein damage and degradation by oxygen radicals. II. Modification of amino acids. , 1987, The Journal of biological chemistry.

[2]  W. Bradley,et al.  Amyotrophc Lateral Sclerosis: Part 1. Clinical Features, Pathology, and E h c d Issues in Management* , 2004 .

[3]  S. Rozen,et al.  Metabolomic analysis and signatures in motor neuron disease , 2005, Metabolomics.

[4]  Barry Halliwell,et al.  Oxidative stress and neurodegeneration: where are we now? , 2006, Journal of neurochemistry.

[5]  W. Matson,et al.  Increased oxidative damage to DNA in an animal model of amyotrophic lateral sclerosis , 2005, Free radical research.

[6]  J. Haines,et al.  Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis , 1993, Nature.

[7]  P. Massion,et al.  The State of Molecular Biomarkers for the Early Detection of Lung Cancer , 2012, Cancer Prevention Research.

[8]  P. J. Callahan,et al.  Volatile organic compounds as breath biomarkers for active and passive smoking. , 2002, Environmental health perspectives.

[9]  Matthew C Kiernan,et al.  Biomarkers in amyotrophic lateral sclerosis , 2009, The Lancet Neurology.

[10]  J. Ciriza,et al.  Optimal methods to characterize the G93A mouse model of ALS , 2005, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[11]  O. Hardiman,et al.  Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: A population-based study. , 2000, Archives of neurology.

[12]  M. Beal,et al.  Increased oxidative damage to DNA in ALS patients. , 2000, Free radical biology & medicine.

[13]  P. Shaw,et al.  Molecular and cellular pathways of neurodegeneration in motor neurone disease , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[14]  M. Bogdanov,et al.  Oxidative stress biomarkers in sporadic ALS , 2008, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[15]  R. Miller,et al.  Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). , 2003, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[16]  J. Kinsella,et al.  Initiation of lipid peroxidation in biological systems. , 1987, Critical reviews in food science and nutrition.

[17]  L. Fuentes-Broto,et al.  Monitoring systemic oxidative stress in an animal model of amyotrophic lateral sclerosis , 2011, Journal of Neurology.

[18]  J. Knight.  Free radicals: their history and current status in aging and disease. , 1998, Annals of clinical and laboratory science.

[19]  S. Appel,et al.  Increased lipid peroxidation in sera of ALS patients , 2004, Neurology.

[20]  H. Haick,et al.  Detection of lung, breast, colorectal, and prostate cancers from exhaled breath using a single array of nanosensors , 2010, British Journal of Cancer.

[21]  W. Robberecht,et al.  The neurobiology of amyotrophic lateral sclerosis , 2010, The European journal of neuroscience.

[22]  H. Haick,et al.  Detection of Alzheimer's and Parkinson's disease from exhaled breath using nanomaterial-based sensors. , 2013, Nanomedicine.

[23]  Albert Ludolph,et al.  Mechanisms, models and biomarkers in amyotrophic lateral sclerosis , 2013, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[24]  Bruce L. Miller,et al.  Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis , 2006, Science.

[25]  J. Andersen,et al.  Oxidative stress in neurodegeneration: cause or consequence? , 2004, Nature Reviews Neuroscience.

[26]  M. Gurney,et al.  Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. , 1994, Science.

[27]  M. Kuźma,et al.  Activity and expression of glutathione S-transferase pi in patients with amyotrophic lateral sclerosis. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[28]  R. Bowser,et al.  Applying proteomics to the diagnosis and treatment of ALS and related diseases , 2009, Muscle and Nerve.

[29]  D. Burke,et al.  Riluzole therapy for motor neurone disease: An early Australian experience (1996–2002) , 2006, Journal of Clinical Neuroscience.

[30]  L. Trizio,et al.  Exhaled volatile organic compounds identify patients with colorectal cancer , 2013, The British journal of surgery.

[31]  M. Gurney,et al.  Relationship of oxygen radical‐induced lipid peroxidative damage to disease onset and progression in a transgenic model of familial ALS , 1998, Journal of neuroscience research.

[32]  R. Bowser,et al.  The application of biomarkers in clinical trials for motor neuron disease. , 2010, Biomarkers in medicine.

[33]  Patrick Emond,et al.  Metabolomics in cerebrospinal fluid of patients with amyotrophic lateral sclerosis: an untargeted approach via high-resolution mass spectrometry. , 2013, Journal of proteome research.

[34]  M. Swash,et al.  El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis , 2000, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.